Status:
COMPLETED
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Lead Sponsor:
Pfizer
Conditions:
Breast Cancer
Eligibility:
All Genders
65+ years
Brief Summary
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI...
Eligibility Criteria
Inclusion
- De novo metastatic (stage IV) disease at initial breast cancer diagnosis during 2015-2019
- HR+/HER2- molecular subtype at diagnosis
- Initiated 1L systemic therapy with palbociclib + AI or AI alone
Exclusion
- Patients will be excluded if their metastatic breast cancer diagnosis was first recorded in a death certificate or at the time of autopsy.
Key Trial Info
Start Date :
September 29 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 24 2024
Estimated Enrollment :
779 Patients enrolled
Trial Details
Trial ID
NCT06086340
Start Date
September 29 2023
End Date
January 24 2024
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer New York
New York, New York, United States, 10001